MSAM
ALLO icon

Moloney Securities Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Moloney Securities Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$637K Buy
514,000
+246,500
+92% +$294K 0.08% 240
2025
Q2 		$302K Sell
267,500
-27,500
-9% -$36.5K 0.04% 361
2025
Q1 		$431K Buy
+295,000
New +$556K 0.06% 276

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Moloney Securities Asset Management's ALLO Position: Q3 2025 in Review

Moloney Securities Asset Management increased its Allogene Therapeutics (ALLO) stake by 92% in Q3 2025, buying an estimated $294K and bringing the position to 514,000 shares worth $637K. The position accounts for 0.08% of the portfolio, ranked #240.

Moloney Securities Asset Management first reported a position in ALLO in Q1 2025 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Moloney Securities Asset Management held 514,000 shares of Allogene Therapeutics worth $637K as of Q3 2025.
  • Moloney Securities Asset Management bought 246,500 Allogene Therapeutics shares in Q3 2025, an estimated $294K.
  • Allogene Therapeutics made up 0.08% of Moloney Securities Asset Management's portfolio in Q3 2025, its #240 holding.
  • Moloney Securities Asset Management first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.